Incyte Corp. (INCY) and Merck (MRK) announced Monday morning that they have decided to advance the clinical development program investigating the combination of epacadostat, Incyte's investigational oral selective IDO1 inhibitor, with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy.
from RTT - Before the Bell http://ift.tt/2i96f6E
via IFTTT
No comments:
Post a Comment